# 1 Antibiotic prescriptions in children with COVID-19 and Multisystem Inflammatory

## 2 Syndrome: a multinational experience in 990 cases from Latin America

- 3 Adriana Yock-Corrales, MD<sup>1</sup>; Jacopo Lenzi, PhD<sup>2</sup>; Rolando Ulloa-Gutiérrez, MD<sup>3</sup>; Jessica Gómez-
- 4 Vargas, MD<sup>1</sup>; Antúnez-Montes Omar Yassef MD<sup>4</sup>; Jorge Alberto Rios Aida MD<sup>5</sup>; Olguita del
- 5 Aguila, MD<sup>6</sup>; Erick Arteaga-Menchaca MD<sup>7</sup>; Francisco Campos MD<sup>8</sup>; Fadia Uribe MD<sup>8</sup>; Andrea
- 6 Parra Buitrago, MD<sup>9,10</sup>; Lina Maria Betancur Londoño, MD<sup>9</sup>; Martin Brizuela MD<sup>11</sup>; Danilo
- 7 Buonsenso  $MD^{12,13,14}$
- 8
- 9 <sup>1</sup> Pediatric Emergency Department, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS,
- 10 San José, Costa Rica.
- <sup>2</sup> Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of
   Bologna, Bologna, Italy
- <sup>3</sup>Infectious Disease Department. Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", CCSS,
   San José, Costa Rica.
- <sup>4</sup>Departamento de Docencia e Investigación, Instituto Latinoamericano de Ecografía en Medicina
   (ILEM)., Ciudad de Mexico, Mexico
- <sup>5</sup>CLÍNICA JAS MÉDICA, Lima, Perù
- <sup>6</sup> Unidad de Infectología Pediátrica del Hospital Nacional Edgardo Rebagliati Martins-Lima-Perú.
- <sup>7</sup>Hospital General Regional 200 IMSS, Mexico
- 20 <sup>8</sup>Hospital Madre Niño San Bartolome, Lima, Peru
- <sup>9</sup>Hospital Pablo Tobon Uribe Medellin, Colombia
- 22 <sup>10</sup>Fundacion Neumologica Colombiana,Bogotà, Colombia
- <sup>23</sup> <sup>11</sup>Pediatric Infectious Disease, Hospital isidoro Iriarte, Quilmes, Buenos Aires, Argentina
- <sup>12</sup> Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario
- 25 A. Gemelli, Rome, Italy
- <sup>13</sup> Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie,
- 27 Università Cattolica del Sacro Cuore, Rome, Italy

- <sup>14</sup>Global Health Research Institute, Istituto di Igiene, Università Cattolica del Sacro Cuore, Roma,
- 29 Italia
- 30 Email addresses:
- 31 Adriana Yock-Corrales, adriyock@gmail.com
- 32 Jacopo Lenzi, jacopo.lenzi2@unibo.it
- 33 Rolando Ulloa-Gutiérrez, rolandoug@gmail.com
- 34 Jessica Gómez-Vargas, jemagova@gmail.com
- 35 Antúnez-Montes Omar Yassef, antunezyassef@gmail.com
- 36 Jorge Alberto Rios Aida, jriosaida@gmail.com
- 37 Olguita del Aguila, odaguila@hotmail.com
- 38 Erick Arteaga-Menchaca, docarteaga@hotmail.com
- 39 Francisco Campos, francisco.e.campos@gmail.com
- 40 Fadia Uribe, kafaur87@hotmail.com
- 41 Andrea Parra Buitrago, aparra@neumologica.org
- 42 Lina Maria Betancur Londoño, lina\_b16@yahoo.com
- 43 Martin Brizuela, martin.brizuela1984@gmail.com
- 44 Danilo Buonsenso, danilobuonsenso@gmail.com

## 46 Abstract

#### 47 Background

To date, there are no comprehensive data on antibiotic use in children with COVID-19 andMultisystem Inflammatory Syndrome (MIS-C).

50 Methods

51 Multicenter cohort study from 5 Latin American countries. Children 17 years of age or younger 52 with microbiologically confirmed SARS-CoV-2 infection or fulfilling MIS-C definition were 53 included. Antibiotic prescriptions were collected and factors associated with their use were 54 calculated.

## 55 Findings

990 children were included, with a median age of 3 years (interquartile range 1–9). Of these, 69 56 (7.0%) were diagnosed with MIS-C. The prevalence of antibiotic use was 24.5% (n = 243). MIS-C 57 58 with (OR = 45.48) or without (OR = 10.35) cardiac involvement, provision of intensive care (OR = 10.35)59 = 9.60), need for hospital care (OR = 6.87), pneumonia and/or ARDS detected through chest X-60 rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) 61 were independently associated with increased use of antibiotics. On the contrary, lower 62 respiratory tract infections without radiologic evidence of pneumonia/ARDS and not requiring 63 64 respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics. 65 There was significant variation in antibiotic use across the hospitals. Conclusions 66

Our study showed a relatively high rate of antibiotic prescriptions in children with COVID-19 and in particular in those with severe disease or MIS-C. Importantly, we found a significant variation in reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices, highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in children with COVID-19. Prospective studies are needed to provide better evidence on the recognition and management of bacterial infections in COVID-19 children.

- 74
- 75
- /5
- 76

#### 77

## 78 Key Words:

- 79 COVID-19; SARS-CoV-2; MIS-C; antibiotic stewardship
- 80 List of Abbreviation
- 81 COVID-19 : coronavirus disease 2019
- 82 SARS-CoV-2 : severe acute respiratory syndrome coronavirus-2
- 83 MIS-C : multisystem inflammatory syndrome in children

#### 84

## 85 What is known

86 COVID-19 may worsen antibiotic prescription practices

## 87 What this new

- 88 COVID-19 and MIS-C children frequently received antibiotics
- 89 There was a wide variation in antibiotic prescriptions among institutions, highlighting the lack of
- 90 practicle guidelines in the use of antibiotics in children with COVID-19
- 91
- 92
- 93
- 94
- 95
- 96

- 98
- 99

100

## 101 \*Declarations

- 102 **Funding:** no funds received
- 103 **Conflicts of interest:** nothing to declare
- 104 Ethics approval: Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-
- 105 06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020
- 106 **Consent to participate:** approved
- 107 **Consent for publication:** approved
- 108 Availability of data and material: available upon request
- 109 Authors' contributions: DB conceptualized the study. JL performed statistical analyses. All authors
- 110 contributed with data collection, writing of the draft of the manuscript- All authors read and approved the
- 111 final version of the manuscript.

112

113

114

### 116 Introduction

117 Months after the first description of COVID-19 in China, growing evidence is raising about the 118 impact of SARS-CoV-2 infection on the pediatric population. Several studies from China (1), 119 Europe (2,3), United States (4) and Latin America (5) are clarifying that COVID-19 in children is 120 typically mild, although patients with medically complex conditions or those of minority 121 race/ethnicity deserve more attention because they may be at risk of more severe disease (4).

122 The Multisystem Inflammatory Syndrome (MIS-C), an entity not yet fully clarified related to 123 SARS-CoV-2, is a severe complication of the exposition to the virus, which may require Intensive

124 Care Admission, mechanical ventilation and cardio-respiratory support, rarely leading to death (6).

Because SARS-CoV-2 is a viral infection, and the resulting disease is usually mild in children, it is not expected that a child with COVID-19 would routinely receive antimicrobials. This is particularly true for the second period of the pandemic, when the non-utility of azithromycin, initially suggested as a drug with potential anti-viral properties (7), has been showed (8). The MIS-C can be an exception to this concept, since the severe and acute presentation may be similar to the toxic-shock syndrome and available consensus documents suggest empiric wide-spectrum antibiotic therapy until bacterial infections are ruled-out (9).

Nevertheless, there are growing concerns about the possible negative impact of the pandemic on antimicrobial use. While this is particularly discussed for adults with COVID-19 (10), Velasco-Arnaiz et al (11) reported preliminary data suggesting that the pandemic has the potential to have a significant impact on antimicrobial use in the pediatric inpatient population. They did assess antibiotic prescriptions during and before the pandemic, but did not assess directly antibiotic use and its determinants in COVID-19 children.

Since cases are constantly raising worldwide, it is expected that SARS-CoV-2 will circulate still for a long time, therefore the appropriate management of children with COVID-19 is a priority. While the pandemic only determined a limited direct impact on children, inappropriate prescriptions have the potential of worsening an already dangerous situation, i.e. antimicrobial resistance.

Due to the gap in available literature, we performed a multinational study in Latin America aiming to assess the use of antibiotics in children with COVID-19 and understand the determinants of its use.

145

### 146 MATERIALS AND METHODS

### 147 Study Design and Participants

148 This study is part of an ongoing independent project assessing COVID-19 and MIS-C in Latin 149 American children, already presented elsewhere (12) and with a previous published paper 150 describing an initial group of 409 children with confirmed COVID-19 (5). For the current study, we 151 aimed to assess determinants of antibiotic use in children with COVID-19. We implemented the 152 previously used dataset (2, 5) including data regarding name of antibiotic used and the reason why the attending clinician decided to administer antibiotics. The remaining variables are those 153 154 previously used and included age, gender, symptoms, imaging, underlying medical conditions, need 155 for hospital and NICU/PICU admission, respiratory and cardiovascular support, other viral co-156 infections, drugs used to treat COVID-19, development of MIS-C and type of organ involvement, 157 and outcome.

The study was reviewed and approved by the CoviD in sOuth aMerIcaN children—study GrOup core group and approved by the Ethics Committee of the coordinating center and by each participating center (Mexico: COMINVETICA-30072020-CEI0100120160207; Colombia: PE-CEI-FT-06; Peru: No. 42-IETSI-ESSALUD-2020; Costa Rica: CEC-HNN-243-2020). The study was conducted in accordance with the Declaration of Helsinki and its amendments. No personal or identifiable data were collected during the conduct of this study.

#### 164 *Statistical analysis*

165 Summary statistics for the study sample were presented as counts and percentages. The 166 association of relevant demographic and clinical characteristics with antibiotic use was assessed 167 using a multivariable logistic regression model; the effect size of covariates was expressed by

168 odds ratios (ORs) with 95% confidence intervals (CIs). The variables considered in this analysis 169 were age, sex, medical history of immunodeficiency, immunosuppressants or chemotherapy, 170 hospital care, pyrexia, upper and lower respiratory tract infections, gastrointestinal symptoms, headache, chest X-ray abnormalities, respiratory support, administration of systemic 171 172 corticosteroids, and diagnosis of MIS-C, both with and without cardiac involvement. A set of 173 dummy variables for individual hospitals was also included in the model to adjust for the 174 potential bias of confounding by center. All data were analyzed using the Stata 15 software 175 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). The 176 significance level was set at 5% and all tests were 2-sided.

#### 177 Role of the Funding Source

The study was not supported by any funding. The corresponding authors had full access to all the data and had the final responsibility for the decision to submit for publication.

180 Dataset availability

181 The dataset generated for this study is available upon request to the corresponding author.

182

### 183 **RESULTS**

## 184 Study population

185 A total of 921 children (93.0%) with microbiologically confirmed COVID-19 and 69 children

187 253, 25.6%), Colombia (n = 43, 4.3%) and Mexico (n = 12, 1.2%) were included in the study.

188 The demographic and clinical characteristics of the 990 study patients are summarized in Table 1.

189 The median age was 3 years (interquartile range: 1–9), ranging from 2 days to 17 years; 484

190 (48.9%) were female. The most common known source of transmission of the infection was a

191 parent, considered the index case in 281 (28.4%) cases. A total of 303 (30.6%) children were

admitted to hospital and 47 (4.7%) required admission to a Pediatric Intensive Care Unit (PICU).

Fever was reported in 677 cases (68.4%); 466 (47.1%) children had symptoms suggestive of upper
respiratory tract infection while 215 (21.7%) had lower respiratory tract symptoms; 301 (30.4%)
had gastrointestinal symptoms. A chest radiograph was done in 285 (28.8%) patients. Of these, 92
(32.3%) had signs of COVID-19 pneumonia. Respiratory co-infections were detected in 14 (1.4%)
children.

We found that 118 (11.9%) individuals required respiratory support; 117 (11.8%) required low-flow oxygen support, 11 (1.1%) were started on continuous positive airway pressure and 31 (3.1%) on mechanical ventilation. A total of 29 (2.9%) patients required inotropic support. Eight children died (0.8%). Further details described in table 1.

202

### 203 Antibiotic use in COVID-19 and MIS-C children

204 The prevalence of antibiotic use was 24.5% (n = 243). As shown in Figure 1, sepsis was the most 205 common reason for administering antibiotics (22.6%), followed by pneumonia (13.6%), surgical 206 causes (11.5%) and upper or mild respiratory infections (9.5%). Information about the classes of 207 antibiotics used was available for 153 (63.0%) patients. Among these, 86 (56.2%) received 208 33 (21.6%) aminoglycosides, 33 (21.6%) penicillins, 31 (20.3%) cephalosporines, 209 antistaphylococcal drugs, 17 (11.1%) antianaerobic drugs, 14 (9.2%) macrolides, 11 (7.2%) carbapenems, and 1 (0.7%) fluoroquinolones. The percentage distribution of single and 210 211 combination antibiotic therapies is illustrated in Figure 2. The rate of antibiotic prescriptions 212 remained stable during the whole study period with an average decrease of -0.6% (95% CI – 213 2.6%, 1.3%) from April 2020 to October 2020 (Figure 3).

On multivariable analysis (Table 2), MIS-C with cardiac involvement (OR = 45.48), MIS-C with no cardiac involvement (OR = 10.35), provision of intensive care (OR = 9.60), need for hospitalization (OR = 6.87), pneumonia and/or ARDS detected through chest X-rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) were independently

associated with increased use of antibiotics. On the contrary, lower respiratory tract infections not suggestive of pneumonia/ARDS and not requiring respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics. We also found large and significant variations in antibiotic use across the hospitals.

223

### 224 **DISCUSSION**

225 In our study, the prevalence of antibiotic prescribing in children with COVID-19 and MIS-C was 226 24.5%. We found significant variations in classes of antibiotics used and even large differences 227 across the hospitals. The rate of antibiotic prescriptions was significantly higher in children with 228 MIS-C, those requiring respiratory support, those with radiologic evidence of pneumonia/ARDS and those with fever. Interestingly, younger children and those with symptoms suggestive of 229 230 lower respiratory tract infections without radiologic evidence of pneumonia/ARDS and not 231 requiring respiratory support were less frequently prescribed with antibiotics. Importantly, also 232 the only need for admission to the hospital was associated with a higher rate of antibiotic 233 prescription. To our knowledge, this is the first multinational study assessing the use of antibiotics 234 in children with COVID-19 and MIS-C, therefore pediatric studies to compare our findings are not available. 235

Velasco-Arnaiz et al (11) are the only authors that evaluated antibiotic use in a pediatric referral 236 237 center before and during the pandemic. The use of azithromycin, initially considered as first-line therapy in severe COVID-19 patients in combination with hydroxychloroquine, increased, 238 239 particularly in PICU setting. The use of ceftriaxone and teicoplanin, doubled in the PICU in April 240 2020 compared with April 2019. In non-PICU patients, piperacillin-tazobactam and ciprofloxacin 241 use increased. Other antibiotics for community-acquired infections were prescribed less than in the 242 same period in 2019, and cefazolin use decreased due to the dramatic drop in the number of 243 surgeries. Also in our cohort, cephalosporins were frequently prescribed, while, interestingly,

macrolides represented only 9.2% of all prescriptions. This is probably because the peak of pediatric cases in Latin America was registered when the concept of utility of azythromicine in COVID-19 was weaker.

247 Confirmed or suspected sepsis was the main reason for antibiotic prescription. This was an expected finding, since the pathogenesis (13) and clinical presentation of MIS-C overlap with those of sepsis, 248 249 and there is general consensus for starting broad-spectrum antibiotics in these children (9). 250 However, MIS-C children represented only 7.0% of the entire cohort, while 24.5% of children 251 received antibiotics. These data suggest a potential overuse of empirical antibiotics in COVID-19 252 children. Considering that COVID-19 is often a milder disease in children compared with adults 253 (14), the pediatric community is expected to empirically use antibiotics less frequently. However, 254 the rate of prescriptions we detected is not widely different from those reported in adult studies. In 255 fact, in our study, the need for hospital admission was independently associated with a higher 256 probability of receiving antibiotic (OR 6.87, 95% CI 4.34-10.89). Addressing adult studies, Seatone 257 et al reported that 38.3% of COVID-19 patients were prescribed antibiotics. Antibiotic prevalence 258 was 45.0%, and 73.9% were prescribed for suspected respiratory tract infection. Amoxicillin, 259 doxycycline and co-amoxiclav accounted for over half of all antibiotics in non-critical care wards, 260 and meropenem, piperacillin-tazobactam and co-amoxiclav accounted for approximately half 261 prescribed in critical care (15).

Although there are no data on bacterial co-infections in children with COVID-19 that may inform better policies of pediatric antimicrobial stewardships during the pandemic, even in adults, where COVID-19 is having a much more severe impact, the burden of bacterial co-infections seems to be relatively low in most published studies (16-23). Buehrle et al found bacterial infections in 31% (5/16) of COVID-19 patients, while antibiotics were administered to 56% (9/16) of patients during hospitalization, but 100% (9/9) of patients requiring ICU care (16). In Spain, Garcia-Vidal et al (17) found that 31/989 (3%) COVID-19 adults presented with community-acquired co-infections,

269 mainly Streptococcus pneumoniae and Staphylococcus aureus pneumonia. Hospital-acquired 270 infection was diagnosed in 43/989 patients (4%), with 25/44 (57%) occurring in critical care 271 (mainly Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., and Staphylococcus aureus). Coagulase-negative staphylococci were the most common organisms causing documented 272 273 bloodstream infection (7/16; 44%). Low observed rates of bacterial and fungal infection in COVID-274 19 patients have also been reported from the UK, where Hughes identified bacterial infection in 51/275 836 COVID-19 patients (6%) (18, 19). A review of eighteen full texts showed that 62/806 (8%) 276 COVID-19 patients experienced bacterial/fungal co-infection during hospital admission, while on 277 secondary analysis, 1450/2010 (72%) of patients were found to have received antimicrobial therapy 278 (20). One Italian study even saw a reduction in *Clostridioides difficile* infections in hospitalized 279 patients (21). In a rapid review, Fattorini et al found that only 1.3% of 522 COVID-19 patients in 280 intensive care units, and apparently no COVID19 patients in other units, developed a healthcare-281 associated super-infection with antimicrobial-resistant bacteria (22, 23).

In our study, having signs or symptoms suggestive of lower respiratory tract infections, without radiologic evidence of pneumonia/ARDS, was associated with a lower probability of receiving antibiotics. This finding may be explained by the fact that in pediatrics such presentations are usually suggestive of a clinical diagnosis of bronchiolitis, wheezing or asthma, conditions that do not require routine antibiotic administration.

Our study clearly shows a high variability of reasons for antibiotic prescriptions and regimens chosen, as well as a significant variability among different centers. These findings highlight the uncertainties that physicians daily face in the management of COVID-19 patients. While the World Health Organization currently recommends against the prescribing of antimicrobials in mild to moderate COVID-19 cases without clear indication of bacterial infection (24), the difficulty in differentiating COVID-19 from bacterial infections on initial presentation challenges clinicians and antimicrobial stewardship practices (25). Almost after one year of the pandemic, there is no

evidence to support decision-making on bacterial infection and antimicrobial stewardship in the context of COVID-19 (19), particularly in children. This uncertainty is likely to drive unnecessary antimicrobial prescribing in COVID-19 children who are unlikely, according to adult evidences, to benefit from empiric antibiotic prescriptions. This scenario will potentially increase the selection of drug resistant infections (26) and will make patients more vulnerable to bacterial infections, even during future viral pandemics that may favor bacterial co-infections from drug resistant bugs (27).

300 Our study has some limitations to address. We did not collect bacteria isolation and antibiotic 301 sensitivities throughout the pandemic in the participating centers. Blood results, including 302 inflammatory markers, were not collected. In addition, an independent expert did not assess the 303 appropriateness of antibiotic prescription, nor the length of administration. Last, the reason for 304 starting antibiotic was subjectively based on the evaluating clinician. The main reason for this 305 approach was that Latin American clinicians are still struggling in the front-line, with hospitals 306 having limited human resources to dedicate extra time for clinical research. Despite these 307 limitations, this study provides the largest overview of antibiotic use in children with COVID-19 308 and MIS-C to date.

In conclusion, our study showed a relatively high rate of antibiotic prescriptions in children with COVID-19 and in particular in those with severe disease or MIS-C. Importantly, we found a significant variation in reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices, highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in COVID-19 children. Prospective studies are urgently needed to provide better evidence on the recognition and management of bacterial infections in COVID-19 children, as well as to develop dedicated antimicrobial stewardship programs.

316

317

#### 318 ACKNOWLEDGMENTS

319 We are grateful to all collaborators that helped the development of the DOMINGO study group.

320

#### 321 References

- Jong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children
   in China. Pediatrics. 2020 Jun;145(6):e20200702. doi: 10.1542/peds.2020-0702.
- 2- Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI,
- 325 Gabrovska N, Velizarova S, Prunk P, Osterman V, Krivec U, Lo Vecchio A, Shingadia D, Soriano-
- 326 Arandes A, Melendo S, Lanari M, Pierantoni L, Wagner N, L'Huillier AG, Heininger U, Ritz N,
- 327 Bandi S, Krajcar N, Roglić S, Santos M, Christiaens C, Creuven M, Buonsenso D, Welch SB, Bogyi
- M, Brinkmann F, Tebruegge M; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep;4(9):653-661. doi: 10.1016/S2352-4642(20)30177-2.
- 3- Parri N, Lenge M, Cantoni B, Arrighini A, Romanengo M, Urbino A, Da Dalt L, Verdoni L,
  Giacchero R, Lanari M, Musolino AM, Biban P, La Fauci G, Pilotto C, Buonsenso D, Chiossi M,
  Agostiniani R, Plebani A, Zampogna S, Barbieri MA, De Masi S, Agostoni C, Masi S;
  CONFIDENCE RESEARCH GROUP. COVID-19 in 17 Italian Pediatric Emergency Departments.
- 335
   Pediatrics. 2020 Sep 23:e20201235. doi: 10.1542/peds.2020-1235.
- 4- Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, Eckrich D,
  Kitzmiller M, Lin SM, Magnusen BC, Newland J, Pajor NM, Ranade D, Rao S, Sofela O, Zahner J,
  Bruno C, Forrest CB. Assessment of 135 794 Pediatric Patients Tested for Severe Acute
  Respiratory Syndrome Coronavirus 2 Across the United States. JAMA Pediatr. 2020 Nov 23. doi:
  10.1001/jamapediatrics.2020.5052.
- 5- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga
  M, Salcedo-Lozada P, Melchior P, de Oliveira RB, Tirado Caballero JC, Redondo HP, Montes
  Fontalvo LV, Hernandez R, Chavez C, Campos F, Uribe F, Del Aguila O, Rios Aida JA, Buitrago
  AP, Betancur Londoño LM, Mendoza Vega LF, Hernández CA, Sali M, Higuita Palacio JE, Gomez-
- 345 Vargas J, Yock-Corrales A, Buonsenso D. COVID-19 and Multisystem Inflammatory Syndrome in

Latin American Children: A Multinational Study. Pediatr Infect Dis J. 2020 Oct 12. doi:
10.1097/INF.00000000002949.

- 6- Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller
  O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A, Shimizu C, Herberg J,
  Burns JC, Lyall H, Levin M; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia.
  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome
  Temporally Associated With SARS-CoV-2. JAMA. 2020 Jul 21;324(3):259-269. doi:
  10.1001/jama.2020.10369.
- 7- Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the
  Antiviral Activity of Azithromycin and Use in COVID-19. Clin Pharmacol Ther. 2020
  Aug;108(2):201-211. doi: 10.1002/cpt.1857.
- 357 8- Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, 358 Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros E Silva PGM, Tramujas L, 359 Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, 360 Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, 361 Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, 362 Machado FR, Berwanger O; Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or 363 without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Nov 19;383(21):2041-364 2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23. Erratum in: N Engl J Med. 2020 Nov 365 19:383(21):e119.
- 9- Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, Kaleem M, Tulloh R,
  Peters MJ, Almond S, Davis PJ, Levin M, Tometzki A, Faust SN, Knight M, Kenny S; PIMS-TS
  National Consensus Management Study Group. A national consensus management pathway for
  paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS):
  results of a national Delphi process. Lancet Child Adolesc Health. 2020 Sep 18:S23524642(20)30304-7. doi: 10.1016/S2352-4642(20)30304-7.
- 372 10- Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, Nguyen MH, Clancy
   373 CJ. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease

- 374 2019 Epicenter. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01011-20. doi:
  375 10.1128/AAC.01011-20.
- 376 11- Velasco-Arnaiz E, López-Ramos MG, Simó-Nebot S, Jordan I, Ríos-Barnés M, Urrea-Ayala M,
   377 Monsonís M, Fortuny C, Noguera-Julian A; Kids Corona project. Pediatric antimicrobial
   378 stewardship in the COVID-19 outbreak. Infect Control Hosp Epidemiol. 2020 Jun 24:1-3. doi:
- 379 10.1017/ice.2020.312. Epub ahead of print.
- 380 12- Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Sárachaga
- 381 M, Salcedo-Lozada P, Sunohara RA, Melchior P, Del Razo JOF, Tirado-Caballero JC, Tasayco-
- 382 Muñoz JA, Pinzon-Redondo H, Montes-Fontalvo LV, Ochoa T, Eduardo Campos F, Hernandez R,
- Limansky L, Del Aguila O, Buonsenso D. COVID-19 in South American Children: A Call For
  Action. Pediatr Infect Dis J. 2020 Oct;39(10):e332-e334. doi: 10.1097/INF.00000000002851.
- Buonsenso D, Riitano F, Valentini P. Pediatric Inflammatory Multisystem Syndrome Temporally
   Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic
   Shock Syndrome. Front Pediatr. 2020 Sep 11;8:574. doi: 10.3389/fped.2020.00574.
- 14- Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection Among Children
  and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatr.*Sep 2020;doi:10.1001/jamapediatrics.2020.4573
- 15- Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, Griffith D, Jeffreys D,
  Hamilton K, Choo-Kang B, Brittain S, Guthrie D, Sneddon J. Survey of antibiotic and antifungal
  prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020
  Sep 26:S0163-4453(20)30616-2. doi: 10.1016/j.jinf.2020.09.024.
- 395 16- Buehrle DJ, Decker BK, Wagener MM, Adalja A, Singh N, McEllistrem MC, Nguyen MH, Clancy
  396 CJ. Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease
  397 2019 Epicenter. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01011-20. doi:
  398 10.1128/AAC.01011-20.
- 399 17- Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M,
  400 Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grafia I, Meira F,
  401 Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, García F, Mensa J, Martínez JA,

402	Soriano A; COVID-19 Researchers Group. Incidence of co-infections and superinfections in
403	hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2020 Jul
404	31:S1198-743X(20)30450-X. doi: 10.1016/j.cmi.2020.07.041.

Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among
 hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.

407 Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025.

- 408 19- Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in
  409 COVID-19. Clin Microbiol Infect. 2020 Oct 9:S1198-743X(20)30577-2. doi:
  410 10.1016/j.cmi.2020.09.025.
- 20- Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G,
  Holmes A. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to
  support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020 May 2:ciaa530. doi:
  10.1093/cid/ciaa530.
- 415 21- Bentivegna E, Alessio G, Spuntarelli V, Luciani M, Santino I, Simmaco M, et al. Impact of COVID-

416 19 prevention measures on risk of health care-associated Clostridium difficile infection. Am J Infect
417 Control. 2020 Oct 5;S0196-6553(20)30891-9. https://doi.org/10.1016/j.ajic.2020.09.010

418 22- Fattorini L, Creti R, Palma C, Pantosti A, Unit of Antibiotic Resistance and Special Pathogens, Unit
 419 of Antibiotic Resistance and Special Pathogens of the Department of Infectious Diseases, Istituto

- 420 Superiore di Sanità, Rome. Bacterial coinfections in COVID-19: an underestimated adversary. Ann
  421 Ist Super Sanita. 2020;56(3):359-64. https://doi.org/10.4415/ANN 20 03 14
- 42223- Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial423resistance? Euro Surveill. 2020 Nov;25(45):2001886. doi: 10.2807/1560-
- 424 7917.ES.2020.25.45.2001886.
- 425 24- World Health Organization. Clinical management of COVID-19. 2020.
   426 <u>https://www.who.int/publications/i/item/clinical-management-of-covid-19</u>.
- 427 25- Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial
  428 stewardship principles! Clin Microbiol Infect 2020;26: 808e10.
  429 https://doi.org/10.1016/j.cmi.2020.04.024.

#### 430 26- Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the

431 mechanisms and drivers of antimicrobial resistance. Lancet 2016;387:176e87.

#### 432 <u>https://doi.org/10.1016/S0140-6736(15)00473-0</u>.

- 433 27- Vaillancourt M, Jorth P. The Unrecognized Threat of Secondary Bacterial Infections with COVID-
- 434 19. mBio. 2020 Aug 7;11(4):e01806-20. doi: 10.1128/mBio.01806-20.
- 435
- 436

Characteristic	n	%
Female sex	484	48.9
Age group		
0 y	202	20.4
1–2 y	229	23.1
3–5 y	144	14.5
6–11 y	247	24.9
12–17 y	168	17.0
COVID-19 confirmed by real-time PCR	639	64.5
Positive SARS-CoV-2 IgG	352	35.6
Delay between onset and diagnosis		
0–1 d	437	44.1
2–7 d	460	46.5
>7 d	93	9.4
Likely index case		
Parent	281	28.4
Sibling	14	1.4
Other	120	12.1
Unknown	575	58.1
Medical history		
Known history of BCG vaccine	740	74.7
Pre-existing medical conditions	128	12.9
Immunosuppressants at the time of diagnosis	11	1.1
Primary or secondary immunodeficiency	8	0.8
Chemotherapy over the last 6 months	8	0.8
Admitted to the hospital	303	30.6
Intensive care during hospital stay	47	4.7
Symptoms		
Pyrexia (≥38.0/≥100.4 °C/°F)	677	68.4
Upper respiratory tract infection	466	47.1
Diarrhea and/or vomiting	301	30.4
Lower respiratory tract infection	215	21.7
Headache	104	10.5
Chest X-ray		
Not performed	705	71.2
Negative	193	19.5
Positive (pneumonia* and/or ARDS <sup>†</sup> )	92	9.3
Respiratory support		
Oxygen support	117	11.8
Mechanical ventilation	31	3.1

Continuous positive airway pressure (CPAP)111.1Extracorporeal membrane oxygenation (ECMO)00.0Administration of inotropes292.9Co-infections detected in respiratory samples(s)‡141.4Drug administration3909.1Systemic corticosteroids909.1Intravenous immunoglobulin (IVIG)606.1Hydroxychloroquine90.9Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis92193.0Yes, with no cardiac or joint involvement33.3Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptoms resolved96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6CenterPeru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3Mexico121.2			
Extracorporeal membrane oxygenation (ECMO)00.0Administration of inotropes292.9Co-infections detected in respiratory samples(s)‡141.4Drug administration909.1Intravenous immunoglobulin (IVIG)606.1Hydroxychloroquine90.9Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis993.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac and joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status70.7Long-term sequelae60.6Center80.8Yes, triangle99.7.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center99.9Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Continuous positive airway pressure (CPAP)	11	1.1
Co-infections detected in respiratory samples(s)‡141.4Drug administration909.1Intravenous immunoglobulin (IVIG)606.1Hydroxychloroquine90.9Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis00.0No92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center13.3Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3		0	0.0
Co-infections detected in respiratory samples(s)‡141.4Drug administration909.1Intravenous immunoglobulin (IVIG)606.1Hydroxychloroquine90.9Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis00.0No92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center13.3Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Administration of inotropes	29	2.9
Drug administration909.1Systemic corticosteroids909.1Intravenous immunoglobulin (IVIG)606.1Hydroxychloroquine90.9Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis00.0MS-C diagnosis232.3Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center99930.2Argentina25325.6Colombia434.3		14	1.4
Systemic corticosteroids909.1Intravenous immunoglobulin (IVIG)606.1Hydroxychloroquine90.9Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status70.7All symptomatic70.7Long-term sequelae60.6CenterPeru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3			
Intravenous immunoglobulin (IVIG) $60$ $6.1$ Hydroxychloroquine9 $0.9$ Oseltamivir8 $0.8$ Lopinavir or ritonavir3 $0.3$ Non-corticosteroid immunosuppressants3 $0.3$ Favipiravir2 $0.2$ Remdesivir2 $0.2$ Chloroquine, ribavirin or zanamivir0 $0.0$ MIS-C diagnosis $V$ $0.0$ No921 $93.0$ Yes, with no cardiac or joint involvement $33$ $3.3$ Yes, with cardiac involvement§ $23$ $2.3$ Yes, with cardiac and joint involvement§ $2$ $0.2$ Tocilizumab administration to treat MIS-C8 $0.8$ Current status7 $0.7$ All symptomatic7 $0.7$ Long-term sequelae $6$ $0.6$ Center $P$ $383$ $38.7$ Costa Rica $299$ $30.2$ Argentina $253$ $25.6$ Colombia $43$ $4.3$	6	90	9.1
Hydroxychloroquine9 $0.9$ Oseltamivir8 $0.8$ Lopinavir or ritonavir3 $0.3$ Non-corticosteroid immunosuppressants3 $0.3$ Favipiravir2 $0.2$ Remdesivir2 $0.2$ Chloroquine, ribavirin or zanamivir0 $0.0$ MIS-C diagnosis0 $0.0$ No92193.0Yes, with no cardiac or joint involvement33 $3.3$ Yes, with cardiac involvement§23 $2.3$ Yes, with cardiac and joint involvement§2 $0.2$ Tocilizumab administration to treat MIS-C8 $0.8$ Current status96997.9Dead¶8 $0.8$ Still symptomatic7 $0.7$ Long-term sequelae6 $0.6$ CenterPeru $383$ $38.7$ Costa Rica299 $30.2$ Argentina $253$ $25.6$ Colombia43 $4.3$	•	60	6.1
Oseltamivir80.8Lopinavir or ritonavir30.3Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis00.0No92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center99930.2Argentina25325.6Colombia434.3		9	0.9
Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center9eru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3		8	0.8
Non-corticosteroid immunosuppressants30.3Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center9eru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Lopinavir or ritonavir	3	0.3
Favipiravir20.2Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center969383Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	•		0.3
Remdesivir20.2Chloroquine, ribavirin or zanamivir00.0MIS-C diagnosis92193.0No92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status096997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center99930.2Argentina25325.6Colombia434.3		2	0.2
MIS-C diagnosis92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptoms resolved96997.9Dead¶60.6Center70.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	1	2	0.2
MIS-C diagnosis92193.0No92193.0Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptoms resolved96997.9Dead¶60.6Center70.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Chloroquine, ribavirin or zanamivir	0	0.0
Yes, with no cardiac or joint involvement333.3Yes, with cardiac involvement§232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center9999Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	-		
Yes, with cardiac involvement232.3Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center9999Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	No	921	93.0
Yes, with joint involvement111.1Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center9999Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Yes, with no cardiac or joint involvement	33	3.3
Yes, with cardiac and joint involvement§20.2Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center999Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Yes, with cardiac involvement§	23	2.3
Tocilizumab administration to treat MIS-C80.8Current status96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center938338.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Yes, with joint involvement	11	1.1
Current status96997.9All symptoms resolved96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center938338.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Yes, with cardiac and joint involvement§	2	0.2
All symptoms resolved96997.9Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center70.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Tocilizumab administration to treat MIS-C	8	0.8
Dead¶80.8Still symptomatic70.7Long-term sequelae60.6Center70.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Current status		
Still symptomatic70.7Long-term sequelae60.6Center70.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	All symptoms resolved	969	97.9
Long-term sequelae60.6Center38338.7Peru38338.7Costa Rica29930.2Argentina25325.6Colombia434.3	Dead¶	8	0.8
Center       383       38.7         Peru       383       38.7         Costa Rica       299       30.2         Argentina       253       25.6         Colombia       43       4.3	Still symptomatic	7	0.7
Peru         383         38.7           Costa Rica         299         30.2           Argentina         253         25.6           Colombia         43         4.3	Long-term sequelae	6	0.6
Costa Rica         299         30.2           Argentina         253         25.6           Colombia         43         4.3	Center		
Argentina         253         25.6           Colombia         43         4.3	Peru	383	38.7
Colombia 43 4.3	Costa Rica	299	30.2
	Argentina	253	25.6
<u>Mexico</u> 12 1.2	Colombia	43	4.3
	Mexico	12	1.2

437 **Table 1.** Characteristics of the study sample (n = 990).

\*45 cases of interstitial disease, 30 cases of consolidation, 4 cases of pleural effusion and 13 unspecified
diagnoses.

440 <sup>†</sup>3 cases of interstitial disease, 3 cases of consolidation and 10 unspecified diagnoses.

441 <sup>‡8</sup> mycoplasmas, 3 rhinoviruses, 1 cytomegalovirus, 1 Epstein–Barr virus and 1 unspecified virus.

\$10 cases of pericardial effusion, 6 cases of coronary dilatation, 5 cases of myocarditis and 4 cases of "other"

443 cardiac involvement.

444 ¶Mean time from symptom onset to death was  $14\pm 8$  days, ranging from 3 to 27.

445 COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction; SARS-CoV-2, Severe acute


446 respiratory syndrome coronavirus 2; *IgG*, immunoglobulin G; *BCG*, bacillus Calmette–Guérin; *ARDS*, Acute

447 respiratory distress syndrome; MIS-C, multisystem inflammatory syndrome.

Characteristic	Odds	<i>P</i> -value	95% confidence interval	
	ratio	- / 4140	Lower bound	Upper bound
Sex				
Male	Ref.			
Female	1.50	0.040	1.02	2.21
Age group				
0 y	Ref.			
1-2 у	0.63	0.118	0.35	1.13
3-5 у	0.82	0.556	0.43	1.58
6–11 y	1.13	0.670	0.65	1.98
12–17 у	0.92	0.821	0.47	1.82
Immunosuppressants, immunodeficiency or chemo				
No	Ref.			
Yes	1.65	0.451	0.45	6.05
Hospitalization				
No	Ref.			
Yes, without intensive care	6.87	< 0.001	4.34	10.89
Yes, with intensive care	9.60	< 0.001	2.77	33.27
Pyrexia (≥38.0/≥100.4 °C/°F)				
No	Ref.			
Yes	1.84	0.011	1.15	2.96
Upper respiratory tract infection				
No	Ref.			
Yes	1.08	0.730	0.71	1.65
Diarrhea and/or vomiting				
No	Ref.			
Yes	1.05	0.822	0.67	1.64
Lower respiratory tract infection				
No	Ref.			
Yes	0.34	0.007	0.16	0.74
Headache				
No	Ref.			
Yes	0.88	0.746	0.42	1.87
Chest X-ray abnormalities (pneumonia and/or ARDS)				
No	Ref.			
Yes	4.40	< 0.001	1.99	9.71
Oxygen support, mechanical ventilation and/or CPAP				
No	Ref.			
Yes	2.21	0.050	1.002	4.88
Administration of systemic corticosteroids				
No	Ref.			
Yes	4.39	< 0.001	2.01	9.58
MIS-C diagnosis				
No	Ref.			
Yes, w/o cardiac involvement	10.35	0.050	1.005	>100
Yes, w/ cardiac involvement	45.48	0.011	2.44	>100
Center				
Hospital San Bartolomé (PE)	Ref.			
Hospital Nacional de Niños (CR)	0.58	0.034	0.34	0.96
Hospital Isidoro Iriarte (AR)	0.25	< 0.001	0.14	0.46
Hospital Edgardo Rebagliati Martins (PE)	0.23	0.014	0.00	0.53
Hospital Pablo Tobón Uribe (CO)	0.04	< 0.014	0.00	0.25
Clínica Jasmédica (PE)	1.48	0.466	0.51	4.28
Hospital General Regional 200 Tecámac (MX)	12.24	0.400	1.06	>100
<b>Table 2.</b> Multivariable logistic regression analysis of				>100


449 **Table 2.** Multivariable logistic regression analysis of antibiotics use (n = 990).

## 450 FIGURES



451 **Figure 1.** Reasons for antibiotic use (n = 243).

452



**Figure 2.** Classes of antibiotics administered to the patients, alone or in combination (n = 243).

#### 

*Notes:* cephalosporines include cefalexine, cefalotin, cefepime, cefotaxime, ceftazidime and ceftriaxone; aminoglycosides include amikacin and gentamicin; penicillins include amoxicillin and ampicillin; antianaerobic drugs include metronidazole; macrolides include azithromycin and clarithromycin; antistaphylococcal drugs include clindamycin, trimethoprim and vancomycin; carbapenems includemeropenem; others include various combinations of these antibiotics as well as fluoroquinolones (ciprofloxacin). 




Figure 3.Prevalence of antibiotic use between April and October 2020. 

Notes: Linear trend was assessed using a linear regression model with variance-weighted least squares.